Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T))

A method of treating acne, atopic dermatitis and/or psoriasis comprising administering a pharmaceutical composition comprising at least one compound of formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof and/or a solvate thereof:

• wherein in formula (I):
• L represents a single bond or a methylene group CH2,
• X represents a cyclic radical chosen from the radicals X1 and X2 below:
• one or two of the elements Y1, Y2, Y3, Y4 and Y5 represent(s) a nitrogen atom and the other elements correspond to a group —CR2, or each of the elements Y1, Y2, Y3, Y4 and Y5 corresponds to a group —CR2,
• each of the elements Q1, Q2 and Q3 corresponds to an identical or different —CR2a group,
• R1 represents a linear or branched C3-C5 alkyl radical, optionally substituted with a hydroxyl group and/or a halogen atom, a C3-C5 cycloalkyl radical, a linear or branched C2-C5 alkenyl radical, a —CH2—(C3-C5)cycloalkyl radical, a C4-C5 heterocycloalkyl radical, a —CH2—(C4-C5)heterocycloalkyl radical,
• R2 represents a hydrogen atom or a halogen atom, a linear or branched C1-C5 alkyl radical, a linear or branched C2-C4 alkenyl radical, a C1-C4 alkoxy radical, a cyano group —CN, a radical —C(═O)R′2 with R′2 denoting a C1-C3 alkoxy radical, a —CF3 radical;
• said alkyl, alkenyl and alkoxy radicals optionally being substituted with one or more halogen atoms,
• R2a represents a hydrogen atom or a halogen atom, a linear or branched C1-C5 alkyl radical, a linear or branched C2-C4 alkenyl radical, a C1-C4 alkoxy radical, a —CN group, a hydroxyl group —OH, a group —CH(R3a)OH, a carboxylic group —COOH, a carbamoyl group —CONR2cR2d, an amido group —NR2cCOR2d, a group —SO2R2c, a group —SOR2c, a group —S(═O)(═NH—R2c), said alkyl, alkenyl and alkoxy radicals optionally being substituted with one or more halogen atoms,
• R2c and R2d, which are identical or different, represent a hydrogen atom or a linear or branched C1-C5 alkyl radical;
• R3a represents a hydrogen atom or a linear or branched C1-C5 alkyl radical,
• R3 represents a hydrogen atom, a halogen atom, a group (CHR6)n—(Z)o—(CHR′6)p—R7 or a group CH═R7,
• n, o and p, which are identical or different, represent zero or a natural integer ranging from 1 to 3,
• Z represents a divalent group selected from the group consisting of a methylene group —CH2—, an amino group —NH— and an oxygen atom —O—,
• R6 and R′6, which are identical or different, represent a hydrogen atom, a methyl group —CH3, a group —OH, a hydroxymethyl group, or a carboxylic function-COOH,
• R7 represents:
• a hydrogen or a halogen atom,
• a group COOR′7 with R′7 denoting (C1)alkyl(C6)heterocycle,
• a heterocycloalkyl radical, wherein the heterocycloalkyl radical is optionally substituted with one or more halogen atoms, one or more linear or branched C1-C3 alkyl groups, one or more —OH groups, one or more carbonyl functions, one or more linear or branched C1-C4 hydroxyalkyl groups, one or more amino groups, one or more groups —C(═O)R7a, one or more groups S(═O)2R7a;
• R7a representing a linear or branched C1-C3 alkyl radical, a linear or branched C1-C3 alkoxy radical, or an amino radical N(R8a)(R8b),
• a C3-C6 cycloalkyl radical, wherein the cycloalkyl radical is optionally substituted with one or more methyl radicals, one or more halogen atoms, a cyano group —CN or one or more groups —COR13;
• R13 denoting a linear or branched C1-C3 alkoxy radical, or a hydroxyl group,
• an aromatic radical, wherein the aromatic radical is optionally substituted with one or more halogen atoms, one or more linear or branched C1-C3 alkyl groups optionally substituted with one or more halogen atoms, one or more C1-C3 alkoxy groups, one or more amino groups —NR11R12, one or more groups —COR11, one or more groups —COOR11, one or more amido groups —CONR11R12, one or more groups —SOR11, one or more groups —SO2R11, one or more groups —NHCOR11, one or more groups —NHCOOR11, one or more groups —SO2NR11R12 or one or more —CN groups;
• R11 and R12, which are identical or different, representing a hydrogen atom, a hydroxyl radical —OH, a linear or branched C1-C3 alkyl radical optionally substituted with one or more halogen atoms;
• a heteroaromatic radical, wherein the heteroaromatic radical is optionally substituted with one or more halogen atoms, one or more linear or branched C1-C3 alkyl groups optionally substituted with one or more halogen atoms, one or more C1-C3 alkoxy groups, one or more amino groups —NR11R12, one or more groups —COR11, one or more groups —COOR11, one or more amido groups —CONR11R12, one or more groups —SOR11, one or more groups —SO2R11, one or more groups —NHCOR11, one or more groups —NHCOOR11, one or more groups —SO2NR11R12 or one or more —CN groups;
• R11 and R12, which are identical or different, representing a hydrogen atom, a hydroxyl radical —OH, a linear or branched C1-C3 alkyl radical optionally substituted with one or more halogen atoms;
• R5 represents a hydrogen atom or a halogen atom, a linear or branched C1-C3 alkyl radical optionally substituted with one or more halogen atoms;
• an amino radical —NH2, a C4-C5 heterocyclic radical, an OCH2—(C4-C5) heterocyclic radical, a radical CH2R′7a with R′7a denoting a methoxy radical, a hydroxyl group —OH, a —CH2COOH group, a group —CH(R5b)OH, a carboxylic group —COOH, a —CN group, a thioxo function,
• R5b represents a hydrogen atom, a linear or branched C1-C3 alkyl radical optionally substituted with one or more carboxylic functions;
• a cyclopropyl radical,
• R8a and R8b, which are identical or different, denote a hydrogen atom, a linear or branched C1-C3 alkyl radical or a cyclopropyl radical;
• and
• wherein the compound of formula (I) inhibit activity of a RORγt receptor.